News

Filter

1401 to 1410 of 96126 results

Takeover target Allergen reports strong 1st-qtr sales growth

07-05-2014

US drugmaker Allergan reported a strong set of first-quarter 2014 financial results, with global sales…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Grunenthal strengthens pain product portfolio with European rights to etoricoxib

07-05-2014

Family-owned German drugmaker Grunenthal Group today announced the signing of an exclusive promotion…

etoricoxibEuropeGenericsGrunenthalLicensingMerck & CoNeurological

More than 100 new drugs in development to treat mental and addictive disorders by US pharma

07-05-2014

The USA’s biopharmaceutical research companies currently are developing 119 novel new medicines to…

NeurologicalPharmaceuticalResearchUSA

GW Pharma shows drop in revenue but expects ‘steady progress’

GW Pharma shows drop in revenue but expects ‘steady progress’

07-05-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

FinancialGW PharmaceuticalsNeurologicalPharmaceuticalSativexUK

Rolf Stahel joins Ergomed as Non-Executive Chairman

Rolf Stahel joins Ergomed as Non-Executive Chairman

07-05-2014

UK-based drug development services company Ergomed has announced the appointment of Rolf Stahel to its…

BiotechnologyBoardroomErgomed Clinical ResarchPharmaceuticalUKUSA

Lundbeck 1st-qtr sales and profits slump on generic competition

Lundbeck 1st-qtr sales and profits slump on generic competition

07-05-2014

Danish CNS drug specialist Lundbeck took a significant hit from generic competition in the first quarter…

FinancialLundbeckNeurologicalPharmaceutical

Merck & Co updates on near-term opportunities and strategy

Merck & Co updates on near-term opportunities and strategy

07-05-2014

US pharma giant Merck & Co, which has just sold its consumer health care business to Bayer for $14.2…

Merck & CoPharmaceuticalRegulationResearch

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

07-05-2014

US health care giant Johnson & Johnson subsidiary Janssen Pharmaceuticals has released positive results…

Invega SustennaJanssenJohnson & JohnsonNeurologicalPharmaceuticalRegulationResearch

1401 to 1410 of 96126 results

Back to top